IP Library Granted Patent US 8,664,203
Granted Patent B2
US 8,664,203 · App. 13/265,493 · Granted Mar 4, 2014

Thiazole derivatives and their use as P2Y12 receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,203
App. No.
13/265,493
Granted
Mar 4, 2014
Kind
B2
Abstract

The present invention relates to thiazole derivatives of formula I and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Claims (119)

1. A compound of formula I

wherein

R 1 represents (C 1 -C 6 )alkoxy;

Y represents a bond and Z represents hydrogen; or

Y represents (C 1 -C 3 )alkandiyl and Z represents hydrogen, hydroxy, —COOH, —COOR 5 , —P(O)(OH) 2 , —P(O)(OR 6 ) 2 , —P(O)(NHR 7 ) 2 or phenyl, wherein the phenyl is substituted with —P(O)(OH) 2 or —P(O)(OR 8 ) 2 ;

W represents a group selected from

R 2 represents hydrogen; halogen; (C 1 -C 4 )alkyl which is monosubstituted with (C 1 -C 4 )alkoxy, —COOH or —COOR 9 ; (C 2 -C 4 )alkenyl which is monosubstituted with (C 1 -C 4 )alkoxy, —COOH or —COOR 9 ; phenyl which is unsubstituted or monosubstituted with halogen; (C 1 -C 4 )alkyl-amino, wherein the alkyl-group is monosubstituted with hydroxy, (C 1 -C 4 )alkoxy, —COOH or —COOR 9 ; di-(C 1 -C 4 )alkyl-amino; heterocyclyl which is unsubstituted or monosubstituted with (C 1 -C 4 )alkyl or (C 1 -C 4 )alkoxy; or 2-methoxymethyl-cycloprop-1-yl;

R 3 represents aryl which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy and phenoxy;

R 4 represents halogen; (C 1 -C 4 )alkyl which is monosubstituted with (C 1 -C 4 )alkoxy, —COOH, or —COOR 9 ; (C 2 -C 4 )alkenyl which is monosubstituted with (C 1 -C 4 )alkoxy or —COOR 9 ; phenyl; or di-(C 1 -C 6 )alkyl-amino;

R 5 represents (C 1 -C 4 )alkyl;

R 6 represents (C 1 -C 4 )alkyl, (C 1 -C 4 )alkyl-C(O)—OCH 2 — or (C 1 -C 4 )alkoxy-C(O)—OCH 2 —;

R 7 represents (C 1 -C 4 )alkoxy-C(O)—(C 1 -C 4 )alkyl-;

R 8 represents (C 1 -C 4 )alkyl;

R 9 represents (C 1 -C 4 )alkyl;

or a pharmaceutically acceptable salt of such a compound.

2. The compound of formula I according to claim 1 , wherein

R 1 represents (C 1 -C 4 )alkoxy;

Y represents (C 1 -C 3 )alkandiyl and Z represents —P(O)(OH) 2 , —P(O)(OR 6 ) 2 , —P(O)(NHR 7 ) 2 or phenyl, wherein the phenyl is substituted with —P(O)(OH) 2 or —P(O)(OR 8 ) 2 ;

W represents a group selected from G1 or G2;

R 2 represents hydrogen; phenyl; di-(C 1 -C 4 )alkyl-amino; or heterocyclyl which is mono-substituted with (C 1 -C 4 )alkyl;

R 3 represents aryl which is unsubstituted or mono-substituted with halogen;

R 4 represents halogen or phenyl;

R 6 represents (C 1 -C 4 )alkyl, (C 1 -C 4 )alkyl-C(O)—OCH 2 — or (C 1 -C 4 )alkoxy-C(O)—OCH 2 —;

R 7 represents (C 1 -C 4 )alkoxy-C(O)—(C 1 -C 4 )alkyl-;

R 8 represents (C 1 -C 4 )alkyl;

or a pharmaceutically acceptable salt of such a compound.

3. The compound of formula I according to claim 2 , wherein

W represents the group G1;

or a pharmaceutically acceptable salt of such a compound.

4. The compound of formula I according to claim 1 , wherein

Y represents (C 1 -C 3 )alkandiyl and Z represents hydroxy or —COOH;

or a pharmaceutically acceptable salt of such a compound.

5. The compound of formula I according to claim 1 , wherein

Y represents (C 1 -C 3 )alkandiyl and Z represents —P(O)(OH) 2 , —P(O)(OR 6 ) 2 , —P(O)(NHR 7 ) 2 or phenyl, wherein the phenyl is substituted with —P(O)(OH) 2 or —P(O)(OR 8 ) 2 ;

or a pharmaceutically acceptable salt of such a compound.

6. The compound of formula I according to claim 1 , wherein

Y represents (C 1 -C 3 )alkandiyl and Z represents —P(O)(OH) 2 or phenyl, wherein the phenyl is substituted with —P(O)(OH) 2 ;

or a pharmaceutically acceptable salt of such a compound.

7. The compound of formula I according to claim 1 , wherein

W represents the group G1;

or a pharmaceutically acceptable salt of such a compound.

8. The compound of formula I according to claim 1 , wherein

R 2 represents hydrogen; halogen; (C 1 -C 4 )alkyl which is monosubstituted with (C 1 -C 4 )alkoxy or —COOH; (C 2 -C 4 )alkenyl which is monosubstituted with (C 1 -C 4 )alkoxy or —COOH; phenyl; (C 1 -C 4 )alkyl-amino, wherein the alkyl-group is monosubstituted with hydroxy, (C 1 -C 4 )alkoxy or —COOH; di-(C 1 -C 4 )alkyl-amino; heterocyclyl which is unsubstituted or monosubstituted with (C 1 -C 4 )alkyl or (C 1 -C 4 )alkoxy; or (1S,2S)-2-methoxymethyl-cycloprop-1-yl;

or a pharmaceutically acceptable salt of such a compound.

9. The compound of formula I according to claim 1 , wherein

R 2 represents hydrogen; phenyl; or di-(C 1 -C 4 )alkyl-amino;

or a pharmaceutically acceptable salt of such a compound.

10. The compound of formula I according to claim 1 , wherein

R 3 represents aryl which is unsubstituted or mono-substituted with halogen;

or a pharmaceutically acceptable salt of such a compound.

11. The compound of formula I according to claim 1 , wherein

R 4 represents halogen or phenyl;

or a pharmaceutically acceptable salt of such a compound.

12. The compound of formula I according to claim 1 , which is selected from the group consisting of:

4-{2-[(2-Phenyl-thiazole-4-carbonyl)-amino]-acetyl}-piperazine-1-carboxylic acid ethyl ester;

4-{(S)-4-Carboxy-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester;

4-((S)-4-Carboxy-2-{[2-(2-phenoxy-phenyl)-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[2-(3-methoxy-phenyl)-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[2-(2-methoxy-phenyl)-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-{(S)-4-Carboxy-2-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-4-Carboxy-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(R)-3-(Diethoxy-phosphoryl)-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-{(R)-2-[(2-Phenyl-thiazole-4-carbonyl)-amino]-3-phosphono-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-3-[4-(Diethoxy-phosphoryl)-phenyl]-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-[(S)-2-[(2-Phenyl-thiazole-4-carbonyl)-amino]-3-(4-phosphono-phenyl)-propionyl]-piperazine-1-carboxylic acid butyl ester;

4-{(S)-3-[4-(Diethoxy-phosphoryl)-phenyl]-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid ethyl ester;

4-[(S)-2-[(2-Phenyl-thiazole-4-carbonyl)-amino]-3-(4-phosphono-phenyl)-propionyl]-piperazine-1-carboxylic acid ethyl ester;

4-{(S)-2-[(5-Bromo-2-phenyl-thiazole-4-carbonyl)-amino]-4-tert-butoxycarbonyl-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-2-[(5-Bromo-2-phenyl-thiazole-4-carbonyl)-amino]-4-carboxy-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-4-Carboxy-2-[(5-chloro-2-phenyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-4-Carboxy-2-[(2,5-diphenyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[5-((1S,2S)-2-methoxymethyl-cyclopropyl)-2-phenyl-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[5-((E)-2-carboxy-vinyl)-2-phenyl-thiazole-4-carbonyl]amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[5-(2-carboxy-ethyl)-2-phenyl-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[5-((E)-3-methoxy-propenyl)-2-phenyl-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[5-(3-methoxy-propyl)-2-phenyl-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-{(S)-4-Carboxy-2-[(5-morpholin-4-yl-2-phenyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-4-Carboxy-2-[(2-phenyl-5-pyrrolidin-1-yl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-((S)-4-Carboxy-2-{[5-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-thiazole-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid butyl ester;

4-{2-[(2-Phenyl-thiazole-4-carbonyl)-amino]-acetyl}-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(3-Hydroxy-propylamino)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(3-Methoxy-propylamino)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(3-Fluoro-phenyl)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-((E)-2-Ethoxycarbonyl-vinyl)-2-phenyl-thiazole-4-carbonyl]amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-((E)-2-Carboxy-vinyl)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(2-Ethoxycarbonyl-ethyl)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(2-Carboxy-ethyl)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(3-Methoxy-propenyl)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(3-Methoxy-propyl)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-{(S)-3-Methyl-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-2-[(5-Bromo-2-phenyl-thiazole-4-carbonyl)-amino]-3-hydroxy-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-{(S)-3-Hydroxy-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[5-((E)-2-Carboxy-vinyl)-2-phenyl-thiazole-4-carbonyl]-amino}-3-hydroxy-propionyl)-piperazine-1-carboxylic acid butyl ester;

4-((S)-2-{[5-(2-Carboxy-ethyl)-2-phenyl-thiazole-4-carbonyl]amino}-3-hydroxy-propionyl)-piperazine-1-carboxylic acid butyl ester;

4-((R)-2-{[2-(4-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester;

4-{(R)-3-(Diethoxy-phosphoryl)-2-[(2,5-diphenyl-thiazole-4-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-{(R)-2-[(2,5-Diphenyl-thiazole-4-carbonyl)-amino]-3-phosphono-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-((R)-3-(Diethoxy-phosphoryl)- 2 -{[5-(4-methyl-piperazin-1-yl)-2-phenyl-thiazole-4-carbonyl]-amino}-propionyl)-piperazine-1-carboxylic acid butyl ester;

4-((R)-2-{[5-(4-Methyl-piperazin-1-yl)-2-phenyl-thiazole-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester;

4-[(R)-2-{[5-(Butyl-methyl-amino)-2-phenyl-thiazole-4-carbonyl]-amino}-3-(diethoxy-phosphoryl)-propionyl]-piperazine-1-carboxylic acid butyl ester;

4-((R)-2-{[5-(Butyl-methyl-amino)-2-phenyl-thiazole-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester;

4-{(R)-2-[(5-Bromo-4-phenyl-thiazole-2-carbonyl)-amino]-3-phosphono-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-{(R)-2-[(4,5-Diphenyl-thiazole-2-carbonyl)-amino]-3-phosphono-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-{2-[(4,5-Diphenyl-thiazole-2-carbonyl)-amino]-acetyl}-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-((E)-3-Methoxy-propenyl)-4-phenyl-thiazole-2-carbonyl]amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(3-Methoxy-propyl)-4-phenyl-thiazole-2-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-((E)-2-Ethoxycarbonyl-vinyl)-4-phenyl-thiazole-2-carbonyl]amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(2-Methoxycarbonyl-ethyl)-4-phenyl-thiazole-2-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(2-Carboxy-ethyl)-4-phenyl-thiazole-2-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-{(S)-2-[(5-Bromo-4-phenyl-thiazole-2-carbonyl)-amino]-4-carboxy-butyryl}-piperazine-1-carboxylic acid butyl ester;

4-{(R)-3-[Bis-(acetoxymethoxy)-phosphoryl]-2-[(2-phenyl-thiazole-4-carbonyl)-amino]propionyl}-piperazine-1-carboxylic acid butyl ester;

N,N′-Bis-((S)-1-Ethoxycarbonylethyl)-(R)-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-3-oxo-3-(4-butoxy-carbonyl-piperazin-1-yl)-propyl-phosphonic acid diamide;

4-{(R)-3-[Bis-(ethoxycarbonyloxymethoxy)-phosphoryl]-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(Hexyl-methyl-amino)-4-phenyl-thiazole-2-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

4-(2-{[5-(2-Carboxy-ethylamino)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester; and

4-(2-{[5-(2-Ethoxycarbonyl-ethylamino)-2-phenyl-thiazole-4-carbonyl]-amino}-acetyl)-piperazine-1-carboxylic acid butyl ester;

or a pharmaceutically acceptable salt of such a compound.

13. A pharmaceutical composition containing at least one compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

14. A method for the treatment of myocardial infarction, arterial thrombosis, transient ischaemic attacks, peripheral vascular disease or stable or unstable angina, comprising the administration to a patient in need thereof of an effective amount of the compound of formula I according to claim 1 , or a pharmaceutically acceptable salt of such a compound.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2024
From: IDORSIA PHARMACEUTICALS LTD.
To: VIATRIS ASIA PACIFIC PTE. LTD.
Reel/Frame 067647/0303 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042464 FRAME: 0407. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 043017/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 042464/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2012
From: CAROFF, EVA; HILPERT, KURT; HUBLER, FRANCIS; LEHMANN, DAVID; MEYER, EMMANUEL; RENNEBERG, DORTE
To: ACTELION PHARMACEUTICALS LTD.
Reel/Frame 027847/0139 →